Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Α. Dimopoulos(Korea University), Morie A. Gertz(Medical University of South Carolina), Mario Boccadoro(University of Turin), Jesús F. San Miguel(Clinica Universidad de Navarra), Robert A. Kyle(Mayo Clinic), Shaji Kumar(Mayo Clinic), Sundar Jagannath(Mount Sinai Hospital), Heinz Ludwig(Wilhelminen Hospital), Kenneth C. Anderson(Dana-Farber Cancer Institute), Seema Singhal(All India Institute of Medical Sciences), Nikhil C. Munshi(Dana-Farber Cancer Institute), Hartmut Goldschmidt(Heidelberg University), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), S. Vincent Rajkumar(WinnMed), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Meral Beksaç(Liv Hospital), Philippe Moreau(Centre National de la Recherche Scientifique), Douglas Joshua(Royal Prince Alfred Hospital), Jean-Paul Fermand(Hôpital Saint-Louis), Asher Chanan‐Khan(WinnMed), Jayesh Mehta(Northwestern University)
Cited by 450
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k